About: Recent advancements in combination subunit vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recent advancements in combination subunit vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recent advancements in combination subunit vaccine development
Creator	Jiang, Xi Tan, Ming
Source	Medline; PMC
abstract	Viral structural proteins share a common nature of homotypic interactions that drive viral capsid formation. This natural process has been mimicked in vitro through recombinant technology to generate various virus-like particles (VLPs) and small subviral particles that exhibit similar structural and antigenic properties of their authentic viruses. Therefore, such self-assembled, polyvalent, and highly immunogenic VLPs and small subviral particles are excellent subunit vaccines against individual viruses, such as the VLP vaccines against the hepatitis B virus, human papilloma virus, and hepatitis E virus, which have already been in the markets. In addition, various antigens and epitopes can be fused with VLPs, small subviral particles, or protein polymers, forming chimeric mono-, bi-, or trivalent vaccines. Owing to their easy-production, un-infectiousness, and polyvalence, the recombinant, chimeric vaccines offer a new approach for development of safe, low-cost, and high efficient subunit vaccines against a single or more pathogens or diseases. While the first VLP-based combination vaccine against malaria has been approved for human use, many others are under development with promising future, which are summarized in this commentary.
has issue date	2017-01-02(xsd:dateTime)
bibo:doi	10.1080/21645515.2016.1229719
bibo:pmid	27649319
has license	bronze-oa
sha1sum (hex)	43e165a782295ab6c95843d80d8406960bc1f2b5
schema:url	https://doi.org/10.1080/21645515.2016.1229719
resource representing a document's title	Recent advancements in combination subunit vaccine development
has PubMed Central identifier	PMC5287306
has PubMed identifier	27649319
schema:publication	Human Vaccines & Immunotherapeutics
resource representing a document's body	covid:43e165a782295ab6c95843d80d8406960bc1f2b5#body_text
is schema:about of	named entity 'particles' named entity 'self-assembled' named entity 'viral capsid' named entity 'vaccines' named entity 'While' named entity 'THEIR' named entity 'NEW' named entity 'MARKETS' named entity 'MONO' named entity 'GENERATE' named entity 'FUSED WITH' named entity 'SUBVIRAL PARTICLES' named entity 'PROTEIN ' named entity 'MALARIA' named entity 'HIGH' named entity 'POLYVALENCE' named entity 'RECOMBINANT' named entity 'SIMILAR' named entity 'EXCELLENT' named entity 'DEVELOPMENT' named entity 'HUMAN USE' named entity 'SUBUNIT VACCINES' named entity 'HIGHLY' named entity 'STRUCTURAL' named entity 'FORMING' named entity 'RECENT' named entity 'VLP' named entity 'INTERACTIONS' named entity 'COMMENTARY' named entity 'SHARE' named entity 'VARIOUS' named entity 'SAFE' named entity 'A COMMON' named entity 'PROCESS' named entity 'PROPERTIES' named entity 'EPITOPES' named entity 'SELF' named entity 'EXHIBIT' named entity 'DISEASES' named entity 'CAPSID FORMATION' named entity 'SUBUNIT VACCINE' named entity 'VIRAL CAPSID' named entity 'COMBINATION VACCINE' named entity 'EASY' named entity 'VIRUS-LIKE PARTICLES' named entity 'VACCINES' named entity 'COMBINATION' named entity 'APPROVED' named entity 'BASED' named entity 'CHIMERIC' named entity 'EFFICIENT' named entity 'DRIVE' named entity 'VLPS' named entity 'PATHOGENS' named entity 'NATURAL' named entity 'VIRAL STRUCTURAL PROTEINS' named entity 'PRODUCTION' named entity 'NATURE' named entity 'FUTURE' named entity 'ADDITION' named entity 'VIRUSES' named entity 'IN VITRO' named entity 'HAVE' named entity 'APPROACH' named entity 'POLYMERS' named entity 'IMMUNOGENIC' named entity 'OFFER' named entity 'HEPATITIS B VIRUS' named entity 'SINGLE' named entity 'SMALL' named entity 'INDIVIDUAL' named entity 'COST' named entity 'ANTIGENS' named entity 'HUMAN PAPILLOMA VIRUS' named entity 'LOW' named entity 'VACCINE DEVELOPMENT' named entity 'HEPATITIS E VIRUS' named entity 'TECHNOLOGY' covid:arg/43e165a782295ab6c95843d80d8406960bc1f2b5 named entity 'papilloma virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software